Transdermal Contraceptive Patch: Application, Schedule, and Contraindications
The transdermal contraceptive patch (containing 150 mcg norelgestromin and 35 mcg ethinyl estradiol) is applied once weekly for 3 consecutive weeks, followed by 1 patch-free week, with placement on the abdomen, upper torso, upper outer arm, or buttocks. 1
Application Protocol
Apply one patch weekly for 3 weeks (21 days total), then observe a 7-day patch-free interval during which withdrawal bleeding typically occurs. 2, 3 The patch should be applied immediately upon removal from the pouch and changed on the same day each week to maintain consistent hormone levels 1, 4.
Approved Application Sites
- Abdomen
- Upper torso (excluding breasts)
- Upper outer arm
- Buttocks
Weekly Replacement Schedule
The patch delivers continuous hormone levels over 7 days, with pharmacokinetic studies demonstrating that adequate steroid levels are maintained for up to 2 days beyond the recommended 7-day wear period 5. This provides a built-in safety margin if patch replacement is delayed by up to 48 hours. 2
Management of Delayed Application or Detachment
For delays <48 hours:
- Apply a new patch immediately
- Keep the same patch change day
- No backup contraception needed
- Emergency contraception generally not required (consider if delay occurred early in cycle or during last week of previous cycle)
For delays ≥48 hours:
- Apply a new patch immediately
- Keep the same patch change day
- Use backup contraception (condoms) or abstain from intercourse until patch worn for 7 consecutive days
- If delay occurred during week 3: omit the hormone-free week and start a new patch immediately
- Consider emergency contraception if delay occurred during week 1 and unprotected intercourse occurred in previous 5 days
Contraindications
The patch shares the same contraindications as combined oral contraceptives, with additional specific considerations:
Absolute Contraindications
- Body weight ≥90 kg (198 lbs) - significantly reduced efficacy in this population 5, 6
- History of venous thromboembolism (VTE)
- Thrombophilic conditions
- Cardiovascular disease
- Cerebrovascular disease
- Breast cancer or other estrogen-sensitive malignancies
- Uncontrolled hypertension
- Migraine with aura (age ≥35)
- Smoking (age ≥35)
- Hepatic disease or tumors
Critical Safety Consideration: VTE Risk
The patch carries approximately 1.6 times higher estrogen exposure compared to combined oral contraceptives, with studies suggesting 1.2-2.2 times increased VTE risk. 3, 7 The FDA package insert contains a black box warning regarding this elevated VTE risk 3. However, the absolute VTE risk remains low, and this must be weighed against the substantial risks of unintended pregnancy 3.
Efficacy and Compliance
Typical use failure rate: 9% (perfect use: <1%) 3. The patch demonstrates significantly superior compliance compared to oral contraceptives, with 88-90% perfect adherence across all age groups versus 77.7% with pills 4, 8. Only 1.9% of patches detach completely, and detachment rates are unaffected by exercise, heat, humidity, or water exposure 4, 5.
Common Pitfalls to Avoid
Do not prescribe for women ≥90 kg - contraceptive efficacy is significantly compromised 5, 6
Gastrointestinal illness does not affect efficacy - unlike oral contraceptives, vomiting or diarrhea does not reduce hormone absorption since delivery is transdermal 6
Breast tenderness is more common with patch use (especially first 2 cycles) but is typically mild-to-moderate and rarely treatment-limiting 4, 8
Application site reactions occur in 1.9% of users - this is unique to the patch and may require discontinuation 4
If detachment timing is uncertain, assume ≥48 hours have passed and follow the extended delay protocol 2